Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
Khoo et al., Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkab318
https://c19early.org/khoo.html